Site Group Page (References Reporting High Throughput Detection Method)
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Site Group Page (References Reporting High Throughput Detection Method)
 

Site Information
PML (human) S403-p AAVSKKAsPEAASTP 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54
PML iso2 (human) S403-p AAVSKKAsPEAASTP
PML iso3 (human) S403-p AAVSKKAsPEAASTP
PML iso4 (human) S403-p AAVSKKAsPEAASTP
PML iso10 (human) S403-p AAVSKKAsPEAASTP
PML iso11 (human) S403-p AAVSKKAsPEAASTP 9, 10, 11, 12, 14, 17, 18, 44, 47, 55
PML iso14 (human) S403-p AAVSKKAsPEAASTP
PML (mouse) - gap
PML iso2 (mouse) - gap
PML (rat) - gap

References

1

Franchin C, et al. (2014) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta
25278378   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

4

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

5

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

6

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

7

Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91
21722762   Curated Info

8

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

9

(2011) CST Curation Set: 12058; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation)
Curated Info

10

(2011) CST Curation Set: 12061; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation)
Curated Info

11

(2011) CST Curation Set: 12062; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation)
Curated Info

12

(2011) CST Curation Set: 12064; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

13

(2011) CST Curation Set: 11453; Year: 2011; Biosample/Treatment: cell line, HeLa/nocodazole & pervanadate; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

14

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

15

(2010) CST Curation Set: 10712; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

16

(2010) CST Curation Set: 10722; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

17

(2010) CST Curation Set: 10713; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

18

(2010) CST Curation Set: 10691; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

19

(2010) CST Curation Set: 10690; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

20

(2010) CST Curation Set: 9970; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

21

(2010) CST Curation Set: 10051; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXsP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

22

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

23

(2010) CST Curation Set: 9850; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

24

(2010) CST Curation Set: 9824; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

25

(2010) CST Curation Set: 9831; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

26

(2010) CST Curation Set: 9848; Year: 2010; Biosample/Treatment: tissue, thyroid/untreated; Disease: thyroid cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

27

(2010) CST Curation Set: 9847; Year: 2010; Biosample/Treatment: cell line, xy3-145N/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

28

(2010) CST Curation Set: 9851; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

29

(2010) CST Curation Set: 9849; Year: 2010; Biosample/Treatment: tissue, thyroid/untreated; Disease: thyroid cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

30

(2010) CST Curation Set: 9854; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

31

(2010) CST Curation Set: 9839; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

32

(2010) CST Curation Set: 9840; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

33

(2010) CST Curation Set: 9837; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

34

(2010) CST Curation Set: 9844; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

35

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

36

(2010) CST Curation Set: 9437; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

37

(2010) CST Curation Set: 9438; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

38

(2010) CST Curation Set: 9290; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation)
Curated Info

39

(2010) CST Curation Set: 9291; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation)
Curated Info

40

(2010) CST Curation Set: 9292; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation)
Curated Info

41

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

42

(2010) CST Curation Set: 8973; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

43

(2010) CST Curation Set: 8987; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

44

(2010) CST Curation Set: 8995; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

45

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

46

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

47

(2009) CST Curation Set: 6354; Year: 2009; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

48

(2008) CST Curation Set: 5273; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

49

(2008) CST Curation Set: 5274; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

50

(2008) CST Curation Set: 5275; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

51

(2008) CST Curation Set: 5276; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

52

Tsai CF, et al. (2008) Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-69
18707149   Curated Info

53

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

54

(2008) CST Curation Set: 4705; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-tXR(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

55

(2006) CST Curation Set: 1665; Year: 2006; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.